MarketMoodz
Lilly’s Foundayo Data Boosts Sales Forecast; Google Unveils New Gemini Push
New data for Lilly’s oral obesity pill Foundayo lifted the stock and prompted Citi to forecast $2.8 billion in 2026 sales, roughly double the street consensus. A Citi survey of endocrinologists—cited by CNBC—suggests about 80% of Foundayo prescriptions come from patients not previously on GLP-1 therapy, signaling potential category expansion even as payer and regulatory risks remain.
Key Takeaways
- Citi projects Foundayo sales of $2.8 billion in 2026 versus a consensus near $1.5 billion.
- About 80% of Foundayo prescriptions reportedly come from patients who were not previously taking GLP-1 drugs, per Citi's survey.
- Lilly shares rose more than 2% intraday after the data and analyst optimism.
- Wegovy retains first-mover advantage as an injectable GLP-1, while oral Foundayo could expand uptake if ease-of-use and dosing advantages hold.
- At Google I/O, Alphabet unveiled Gemini 3.5, Gemini Omni and other AI upgrades, with the company citing strong usage growth for its Gemini app.
People Involved
- No specific individuals mentioned
Entities Involved
- Eli Lilly and Company (LLY)Developer of Foundayo, oral GLP-1 obesity treatment
- Novo Nordisk (NVO)Maker of Wegovy, an injectable GLP-1 with first-mover brand recognition
- Citigroup (Citi)Conducted the endocrinologist survey and published the Foundayo sales projection
- Alphabet/Google (GOOGL)Announced Gemini 3.5, Gemini Omni and other AI product updates at Google I/O
- CNBCReported on the Citi note, market moves and Google I/O coverage
MarketMoodz Analysis
For investors, the immediate takeaway is upside risk to Lilly’s obesity-drug revenue and earnings if Foundayo converts new patients at the pace Citi models. A $2.8 billion 2026 revenue line would materially exceed the roughly $1.5 billion consensus and could justify a re-rating for positions that already favor defensive healthcare exposure; Lilly’s shares moved more than 2% on the data and analyst optimism. That said, the projection rests on a physician survey and early adoption signals—payer coverage, real-world tolerability and regulatory timing are key levers that will determine how much of the bull case is realized.
Historically, injectables like Wegovy benefited from first-mover brand recognition and established reimbursement pathways. Oral GLP-1s change the adoption calculus by lowering clinical and logistical friction; Citi’s survey indicates many prescriptions could come from patients who weren’t on GLP-1s previously, which would expand the overall market rather than just shifting share. Investors should watch upcoming commercial uptake metrics, payer coverage decisions and quarterly cadence for clearer conversion rates. On the macro side, the market’s tilt toward defensive healthcare amid rising rates (10-year Treasury at 4.665%, 30-year at 5.19%) and high energy costs supports outperformance for durable-revenue names—but valuation sensitivity to rates remains an active risk.
Google’s I/O product-cycle AI news matters for Alphabet but is a separate cadence: Gemini upgrades and broader AI integration can improve user engagement and long-term monetization, yet they don’t move drug-market economics. Trackable near-term catalysts to watch: Foundayo real-world prescription trends and payer policy announcements, Lilly’s upcoming earnings commentary, any regulatory milestones for oral GLP-1 approvals, and usage/monetization metrics from Alphabet that show the AI feature set boosting ad or cloud revenue.
Source: Original Article